UnitedHealth Discloses IRS Probe As Physician-Group Deal Volume Falls About 50%, Pressuring Health-Care Rollups

UnitedHealth has disclosed that the Internal Revenue Service is investigating the company and is “seeking to significantly increase taxable income” from 2017 through 2020, with the possibility that the insurer could pay more for subsequent years after 2020. The disclosure appeared in a recent regulatory filing cited by STAT.

That company-specific tax issue arrived alongside a broader sign of financing restraint in provider-adjacent health care. Over a dozen states now have laws enhancing their oversight of private equity deals in health care, and a new report cited by STAT says the tougher review environment is putting a crimp in dealmaking for physician practice management businesses.

Dealmaking slows in physician practice management

According to new PitchBook data cited by STAT, physician practice management is on track to see about half the number of deals this year as it did in 2025. Investments in those businesses, which run clinics’ billing and operations, fell from a high of 851 deals in 2021 to 105 in the first half of 2026.

Paul Pitts, a partner with Reed Smith who works with health care providers, told STAT that the decline has been substantial. The numbers suggest that state-level scrutiny is changing the pace of consolidation, at least in one of the structures private equity has used to gain exposure to physician groups.

Why the two signals matter

The UnitedHealth filing and the private equity slowdown are separate developments, but they point in the same direction: health care deal models that once benefited from complexity are facing more friction. In UnitedHealth’s case, that friction comes from a federal tax inquiry tied to prior years. In physician practice management, it comes from a growing patchwork of state oversight laws that can slow or deter transactions.

For investors and operators, the takeaway is less about any single enforcement action than about execution risk. Returns in health care have often depended on regulatory, tax, and corporate structuring details that sit outside the core clinical business. When those details draw more scrutiny, capital deployment can slow even if demand for underlying services remains intact.